Kiniksa Pharmaceuticals International (KNSA) Market Capitalization (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Market Capitalization for 9 consecutive years, with $10.0 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization rose 143.39% year-over-year to $10.0 billion; the trailing twelve-month figure through Jun 2026 stood at $10.0 billion (up 143.39% YoY), and the FY2025 full-year result was $6.3 billion, up 119.37% from the prior year.
• Market Capitalization improved to $10.0 billion in Q2 2026 per KNSA's latest filing, from $7.4 billion in the prior quarter.
• Across five years, Market Capitalization topped out at $10.0 billion in Q2 2026 and bottomed at $1.3 billion in Q2 2022.
• Historically, Market Capitalization has averaged $3.5 billion across 5 years, with a median of $2.7 billion in 2024.
• The sharpest annual moves came in 2022 and 2026: Market Capitalization slumped 45.56% in 2022, then jumped 143.39% in 2026.
• Over 5 years, Market Capitalization stood at $2.1 billion in 2022, then increased by 18.45% to $2.5 billion in 2023, then increased by 16.14% to $2.9 billion in 2024, then surged by 119.37% to $6.3 billion in 2025, then surged by 58.25% to $10.0 billion in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $10.0 billion, $7.4 billion, and $6.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.